Sage Therapeutics SAGE
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
Key Insights
Sage Therapeutics (SAGE) Core Market Data and Business Metrics
Latest Closing Price
$7.77Price-Earnings Ratio
-1.18Total Outstanding Shares
61.48 Million SharesDividend
No dividendSIC Description
Pharmaceutical PreparationsPrimary Exchange
NASDAQHeadquarters
55 Cambridge Parkway, Cambridge, MA, 02142
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Short Interest
Track Short Interest Levels to Gauge Bearish Market Sentiment and Short Squeeze Potential
| Avg Daily Volume | Days to Cover | Settlement Date | Short Interest |
|---|---|---|---|
| 1,411,687 Shares | 3.02 | 3/14/2025 | 4,260,719 Shares |
| 1,455,891 Shares | 2.69 | 2/28/2025 | 3,917,888 Shares |
| 1,677,599 Shares | 2.63 | 2/14/2025 | 4,414,803 Shares |
| 2,387,892 Shares | 1.75 | 1/31/2025 | 4,168,829 Shares |
| 3,122,676 Shares | 1.96 | 1/15/2025 | 6,130,983 Shares |
| 1,750,031 Shares | 2.76 | 12/31/2024 | 4,832,108 Shares |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Financing Activities, Continuing | $10.66 Million |
| Net Cash Flow From Operating Activities | $-267.19 Million |
| Net Cash Flow From Financing Activities | $10.66 Million |
| Net Cash Flow, Continuing | $10.15 Million |
| Net Cash Flow From Operating Activities, Continuing | $-267.19 Million |
| Net Cash Flow | $10.15 Million |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Operating Expenses | $473.61 Million |
| Diluted Average Shares | $60.77 Million |
| Income/Loss From Continuing Operations After Tax | $-400.67 Million |
| Research and Development | $225.90 Million |
| Other Operating Expenses | $31.30 Million |
| Revenues | $41.24 Million |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Comprehensive Income/Loss Attributable To Parent | $-399.61 Million |
| Other Comprehensive Income/Loss | $1.06 Million |
| Comprehensive Income/Loss | $-399.61 Million |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Current Assets | $531.30 Million |
| Equity Attributable To Parent | $465.09 Million |
| Other Current Liabilities | $44.08 Million |
| Other Non-current Assets | $15.03 Million |
| Current Liabilities | $71.61 Million |
| Equity Attributable To Noncontrolling Interest | $0 |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||